Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor
MarketBeat
Kura Oncology (NASDAQ:KURA) and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said showed beta-cell expansion, improved glucose control and sustained effects after treatment ended.
NASDAQ:KURA